Effects of pretreatment with SDZ MRL 953, a novel immunostimulatory lipid A analog, on endotoxin-induced acute lung injury in guinea pigs.
SDZ MRL 953 (SDZ), a novel immunostimulatory lipid A analog, has been reported to have immunopharmacological activities similar to those of lipopolysaccharide (LPS) but to have little of the toxicity of LPS. We investigated the effects of pretreatment with SDZ on Escherichia coli endotoxin-induced acute lung injury in guinea pigs. Four experimental groups consisted of saline control (n = 16), SDZ (-12 h) plus LPS (2 mg/kg of SDZ per kg of body weight injected intravenously 12 h before intravenous injection of 2 mg of LPS per kg; n = 15), SDZ (-10 min) plus LPS (SDZ injected 10 min before LPS injection; n = 10), and LPS alone (n = 16). The animals were sacrificed, and lung tissue was sampled 4 h after LPS or saline infusion. Lung injury was assessed by measuring the wet weight-to-dry weight ratio and the level of 125I-labeled albumin accumulation in bronchoalveolar lavage fluid relative to that in plasma. In the SDZ (-12 h) plus LPS group, these two parameters of acute lung injury were decreased compared with those in the LPS alone group. However, they were not decreased in the SDZ (-10 min) plus LPS group. We conclude that SDZ attenuates endotoxin-induced acute lung injury when it is administered 12 h before LPS injection. The attenuating effects of SDZ are speculated to be due to down regulation of the response to endotoxin rather than to receptor blocking.
Nakamura
H
H
Department of Medicine, School of Medicine, Keio University, Tokyo, Japan.
Ishizaka
A
A
Urano
T
T
Sayama
K
K
Sakamaki
F
F
Terashima
T
T
Waki
Y
Y
Soejima
K
K
Tasaka
S
S
Hasegawa
N
N
D000276:Adjuvants, Immunologic / Q000494:pharmacology*; D000418:Albumins / Q000378:metabolism; D000818:Animals; D001992:Bronchoalveolar Lavage Fluid / Q000737:chemistry / Q000166:cytology; D004731:Endotoxins / Q000009:adverse effects; D005260:Female; D006168:Guinea Pigs; D006439:Hemodynamics; D007958:Leukocyte Count; D008050:Lipid A / Q000031:analogs & derivatives* / Q000494:pharmacology; D008070:Lipopolysaccharides / Q000494:pharmacology; D008168:Lung / Q000737:chemistry; D009504:Neutrophils / Q000166:cytology; D012128:Respiratory Distress Syndrome / Q000139:chemically induced* / Q000276:immunology / Q000473:pathology; D018805:Sepsis / Q000139:chemically induced; D015996:Survival Rate; D014409:Tumor Necrosis Factor-alpha / Q000032:analysis / Q000378:metabolism; D014867:Water / Q000032:analysis
D000276:Adjuvants, Immunologic; D000418:Albumins; D004731:Endotoxins; D008050:Lipid A; D008070:Lipopolysaccharides; D014409:Tumor Necrosis Factor-alpha; D014867:Water; C068979:SDZ MRL 953